We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Relapses are common in severe hematologic systemic lupus erythematosus and may be prevented by early institution of immunosuppressive agents: Α real-life single-center study.
- Authors
Moysidou, Georgia-Savina; Garantziotis, Panagiotis; Nikolopoulos, Dionysis; Katsimbri, Pelagia; Fanouriakis, Antonis; Boumpas, Dimitrios T
- Abstract
Background: Hematologic manifestations are common in systemic lupus erythematosus (SLE), either at initial presentation or during the course of the disease, but data regarding their natural history are scarce. Objective: To describe the characteristics, treatments, and outcomes of severe hematological manifestations in a large cohort of lupus patients. Methods: Retrospective cohort study of patients in the "Attikon" lupus cohort who had a history of a severe hematologic manifestation, defined as autoimmune hemolytic anemia (AIHA) with hemoglobin < 8 g/dL, thrombocytopenia with platelet count < 30,000/mm3, Evans syndrome with hemoglobin < 8 g/dL, and/or platelet count < 30,000/mm3, neutropenia with < 500 neutrophils/mm3, thrombotic microangiopathy (TMA)/thrombotic thrombocytopenic purpura (TTP)-like syndrome, or macrophage activation syndrome (MAS). Demographic and clinical characteristics, treatments, and outcomes were recorded. Results: From over 300 patients with hematologic manifestations, 41 qualified as severe (70.7% women, mean [SD] age at SLE diagnosis 42.6 [18.0] years). Hematologic manifestations preceded SLE diagnosis in 13 patients (31.7%), was concomitant to SLE diagnosis in 16 patients (39%), and occurred during the course of the disease in 12 (29.3%) patients, with a mean (SD) disease duration of 8.7 (5.5) years. Thrombocytopenia was the most common severe hematological manifestation (56.1%), followed by AIHA (17.1%) and TTP-like syndrome (12.2%). For initial treatment, all patients were treated with glucocorticoids (GC), while rituximab and cyclophosphamide were the most frequently used immunosuppressive agents. Following initial treatment, relapse occurred in 22 patients (53.7%). Compared to patients that did not relapse, those that relapsed had less often received concomitant immunosuppressive agents following treatment of initial episode (n = 17/23, 73.9% vs 5/17, 29.4%, p = 0.005). Conclusion: Severe hematologic disease in SLE has a high risk of relapse, which may be mitigated by the early institution of GC-sparing agents.
- Subjects
SYSTEMIC lupus erythematosus; LUPUS nephritis; IMMUNOSUPPRESSIVE agents; MACROPHAGE activation syndrome; AUTOIMMUNE hemolytic anemia; BLOOD diseases
- Publication
Lupus, 2023, Vol 32, Issue 2, p225
- ISSN
0961-2033
- Publication type
Article
- DOI
10.1177/09612033221144425